

**Anti MDA-treated low-density lipoprotein (LDL, MDA-treated) mouse monoclonal antibody**Subclass: IgG<sub>1</sub>/IPRODUCT NO. **HYB 262-04**

PRESENTATION Preparation: Protein-A/G purified  
 Content: 1 mL, 1 mg/mL  
 Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide  
 Storage: In the dark at 4-8°C

ANTIGEN Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-treated LDL appear to be different from LDL oxidized by other means.

IMMUNOGEN Low-density lipoprotein purified from human plasma and treated with malonyldialdehyde (MDA)

SPECIFICITY HYB 262-04 reacts with MDA-treated LDL but not with native LDL

EPITOPE SPECIFICITY Not determined

REACTIVITY HYB 262-04 reacts with MDA-treated LDL in ELISA and in SDS-PAGE immunoblotting

CULTURE MEDIUM RPMI 1640 with 10% fetal calf serum

FUSION PARTNER X63-Ag8.653.

IMMUNIZATION Female CF1 x BALB/c mice immunized i.p. with immunogen adsorbed onto Al(OH)<sub>3</sub>

Method	Usability	Dilution guideline	References
ELISA	Yes	1:8000	
Immunoblotting	Yes		
Immunohistochemistry	Not determined		

Users should determine the optimal dilutions for their own purposes.

REFERENCES

1. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL (1990) Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. *Arteriosclerosis* 10:325-335.
2. Vaarala O, Alfthan G, Jauhainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. *Lancet* 341:923-925.
3. Binder JC, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, Shaw PX, Palinski W, Witztum JL, Silverman GJ (2003) Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between *Streptococcus pneumoniae* and oxidized LDL. *Nat Med* 9:736-743.

**CONDITIONS**

All products are supplied on the understanding that they are for in vitro use only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.